MAPT and Alzheimer disease: Plasma tau phosphorylated, at threonine 181 (p-tau181) level quantification, was significantly enhanced in AD patients compared to the control cohort following an ultrasensitive Simoa immunoassay, demonstrating p-tau181 as a promising blood bio-marker for the detection of brain AD pathology [25].